Aryl ethers and uses thereof
USRE49948E1 · kind E1 · reissue
1Cited by
13References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2022 |
| Grant date | Apr 30, 2024 |
| Priority date | — |
| Expiry date | Feb 3, 2042 |
Classification
- Technology area (CPC —)General
Abstract
The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.